Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Therapy for Diabetes Mellitus and Diabetic Complications

As a novel cell-free strategy, mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) inherit the therapeutic potential of donor cells, and are widely used for the treatment of many diseases. Increasing studies have shown that MSC-EVs transfer various bioactive molecules to create a benefici...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 14; no. 10; p. 2208
Main Authors Sun, Fengtian, Sun, Yuntong, Wu, Feng, Xu, Wenrong, Qian, Hui
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.10.2022
MDPI
Subjects
Aging
Biosynthesis
Care and treatment
Diabetes
diabetic complications
diabetic mellitus
Diabetic neuropathy
Diabetic retinopathy
Diagnosis
engineering
Extracellular vesicles
Health aspects
Hyperglycemia
Insulin
Lipids
mesenchymal stem cell
Methods
Mitochondrial DNA
Proteins
Regenerative medicine
Review
Senescence
Signal transduction
Stem cells
Transplantation
China
Online AccessGet full text
ISSN1999-4923
1999-4923
DOI10.3390/pharmaceutics14102208

Cover

More Information
Summary:As a novel cell-free strategy, mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) inherit the therapeutic potential of donor cells, and are widely used for the treatment of many diseases. Increasing studies have shown that MSC-EVs transfer various bioactive molecules to create a beneficial microenvironment, thus exerting protective roles in diabetic mellitus (DM) and diabetic complications. To overcome the limitations of natural MSC-EVs such as heterogeneity and insufficient function, several modification methods have been established for constructing engineered MSC-EVs with elevated repairing efficiency. In this review, the PubMed library was searched from inception to August 2022, using a combination of Medical Subject Headings (MeSH) and keywords related to MSC-EVs, DM, and diabetic complications. We provide an overview of the major characteristics of MSC-EVs and summarize the recent advances of MSC-EV-based therapy for hyperglycemia-induced tissue damage with an emphasis on MSC-EV-mediated delivery of functional components. Moreover, the potential applications of engineered MSC-EVs in DM-related diseases therapy are discussed by presenting examples, and the opportunities and challenges for the clinical translation of MSC-EVs, especially engineered MSC-EVs, are evaluated.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14102208